A New Drug Application (NDA) in Taiwan requires clinical trial results, quality control data, manufacturing details, pharmacological data, and Good Manufacturing Practices (GMP) compliance documentation. Additional materials include a product summary, labeling information, and translated documents if necessary. Submissions must be made via the Taiwan FDA’s (TFDA) e-submission platform.